Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Slides:



Advertisements
Similar presentations
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,
Advertisements

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prognostic Risk Index for Long-term Mortality in.
Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.
Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification by Paolo Strati, and.
The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
EBV DNA: a Hodgkin lymphoma biomarker?
by Paolo Strati, and Tait D. Shanafelt
by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa
Can Kinase Inhibitors and Immunomodulators Replace Chemotherapy? No
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.
One giant leap for pediatric AMKL
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,
Protease inhibitors potentiate chemotherapy-induced neutropenia
Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk.
by Alexander Röth, Andreas Hüttmann, Russell P
Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.
by Karl-Georg Fischer, Barbara Deschler, and Michael Lübbert
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,
Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.
Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset.
Stage C or not stage C…? by Claire Dearden Blood
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial by Peter Dreger,
Tait D. Shanafelt, MD, Timothy G. Call, MD  Mayo Clinic Proceedings 
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,
Has MRD monitoring superseded other prognostic factors in adult ALL?
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies by Sabine Kayser, Manuela Zucknick,
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.
Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen,
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation 
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S by Michael Makris, Michael Leach,
Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.
Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.
Influence of ASGR2 expression on survival.
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance by Taghi Manshouri, Kim-anh.
Patient stratification using survival risk prediction and BCLC staging
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis by.
Cold agglutinin disease
Presentation transcript:

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara F. Eichhorst, Manuela A. Bergmann, Thomas Elter, Kathrin Bauer, Gebhart Malchau, Kari G. Rabe, Stephan Stilgenbauer, Hartmut Döhner, Ulrich Jäger, Michael J. Eckart, Georg Hopfinger, Raymonde Busch, Anna-Maria Fink, Clemens-Martin Wendtner, Kirsten Fischer, Neil E. Kay, and Michael Hallek Blood Volume 124(1):49-62 July 3, 2014 ©2014 by American Society of Hematology

The survival curves according to clinical staging in the training data set. Natali Pflug et al. Blood 2014;124:49-62 ©2014 by American Society of Hematology

Time-to-event curves according to the prognostic index in the training data set. Natali Pflug et al. Blood 2014;124:49-62 ©2014 by American Society of Hematology

Survival curves of the Binet and Rai stages by prognostic index risk categories in the training data set. Natali Pflug et al. Blood 2014;124:49-62 ©2014 by American Society of Hematology

Survival curves of genetic subgroups by prognostic index risk categories in the training data set. Natali Pflug et al. Blood 2014;124:49-62 ©2014 by American Society of Hematology

Time-to-event curves according to the prognostic index in the validation data set. Natali Pflug et al. Blood 2014;124:49-62 ©2014 by American Society of Hematology

Survival curves of Rai stages by prognostic index risk categories in the validation data set. Natali Pflug et al. Blood 2014;124:49-62 ©2014 by American Society of Hematology

Survival curves of genetic subgroups by prognostic index risk categories in the validation data set. Natali Pflug et al. Blood 2014;124:49-62 ©2014 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.